GHRH1 GHRH Analogue | HPLC-Verified | Regena

GHRH1 is a 44-amino-acid synthetic peptide derived from native GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. The modification protects the peptide from DPP-4 cleavage and produces a substantially longer functional half-life than unmodified GHRH(1-29) or sermorelin.

Published preclinical and clinical research has explored GHRH1 in studies of visceral adipose tissue, lipid metabolism, IGF-1 axis modulation and the broader growth-hormone secretory pathway. It remains the gold-standard reference GHRH analogue in laboratory work.

Each GHRH1 batch is tested by an independent European peptide laboratory before any vial is released. The COA reports HPLC main-peak purity (target ≥99.0%), mass-spectrometry confirmation of molecular weight including the trans-3-hexenoyl modification, peptide content by nitrogen, and residual moisture.

Janoshik Analytical is the default verification partner. Per-batch PDFs are downloadable from the lab reports page and traceable to the batch number printed on every vial cap.

Lyophilised GHRH1 is supplied as a sterile white powder under inert atmosphere. Hold unopened vials at 2–8 °C; transfer to −20 °C only if reconstitution will not happen within 8 months. Reconstitute with bacteriostatic water for a two-month (60-day) in-use stability window under refrigeration; minimise light exposure to preserve the N-terminal tyrosine.

Most laboratories favour 2–5 mg/ml stock concentrations for ease of microlitre dispensing. GHRH1 is sensitive to repeat freeze–thaw cycles — aliquot the full reconstituted volume before any freeze to preserve potency.

Regena dispatches GHRH1 from the Costa del Sol with 5–14 day tracked Andalucía delivery and 5–14 day Spain-wide tracked courier coverage. Cross-border EU shipping uses DHL Express to Germany, France, Italy, Portugal, the Netherlands, Belgium and Scandinavia.

Every EU shipment carries the matching batch COA and a research-use customs declaration. The consultations team will confirm import status for less common destinations before order placement.

UK research clients receive GHRH1 via tracked dispatch from the European hub in 5–14 days. DHL Express upgrades are available for tighter timelines. VAT and customs handling are quoted transparently at checkout — no surprise import charges on delivery.

All UK orders ship with the same independent Janoshik COA used for EU clients. Additional paperwork (MSDS, CoO, CoC) is supplied on request before dispatch.

US-based research clients receive GHRH1 via discreet, fully tracked international dispatch in temperature-buffered packaging. The COA supplied with each shipment is identical to the document EU laboratories receive.

US buyers should confirm institutional research-purchasing policy before ordering. GHRH1 is supplied strictly for research use only and is not approved for human consumption in any jurisdiction.

Researchers often compare GHRH1 with CJC-1295 (with and without DAC) and ipamorelin in growth-hormone secretory-axis panels. GHRH1 is a stabilised GHRH analogue; CJC-1295 is a 30-residue GHRH analogue with optional DAC (drug-affinity-complex) modification for extended half-life; ipamorelin is a selective ghrelin/GHSR receptor agonist that acts on a different upstream pathway entirely.

Stocking the three from the same supplier keeps batch documentation and packaging consistent across a comparative growth-hormone secretory-axis study.

An honest GHRH1 supplier publishes a per-batch third-party COA that explicitly verifies the trans-3-hexenoyl N-terminal modification by mass spectrometry — a missing or incorrect modification is the single most common defect in cheap GHRH1 and cannot be detected by HPLC purity alone.

Regena's consultations team can walk new buyers through the COA, the reconstitution maths and the storage plan before any order is dispatched.